Literature DB >> 19343022

Helping patients make informed choices about probiotics: a need for research.

Richard R Sharp1, Jean-Paul Achkar, Margaret A Brinich, Ruth M Farrell.   

Abstract

Applications of probiotics in the treatment of gastrointestinal disorders are gaining acceptance among patients, despite evidence that probiotics can present substantial health risks, particularly for patients who are immunocompromised or seriously ill. Patients will likely formulate their attitudes and beliefs about probiotic therapies with reference to interpretive frameworks that compare probiotics with more familiar therapeutic modalities, including complementary and alternative medicines, pharmacological therapies, and gene-transfer technologies. Each of these frameworks highlights a different set of benefit-to-risk considerations regarding probiotic usage and reinforces extreme characterizations of both the therapeutic promise and peril of probiotics. Considerable effort may be required to help patients make informed choices about probiotic therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19343022      PMCID: PMC2746707          DOI: 10.1038/ajg.2008.68

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  44 in total

Review 1.  Explaining risks: turning numerical data into meaningful pictures.

Authors:  Adrian Edwards; Glyn Elwyn; Al Mulley
Journal:  BMJ       Date:  2002-04-06

2.  Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes.

Authors:  C Quattropani; B Ausfeld; A Straumann; P Heer; F Seibold
Journal:  Scand J Gastroenterol       Date:  2003-03       Impact factor: 2.423

3.  Risk communication in the clinical consultation.

Authors:  Richard Thomson; Adrian Edwards; Jenny Grey
Journal:  Clin Med (Lond)       Date:  2005 Sep-Oct       Impact factor: 2.659

Review 4.  VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics.

Authors:  Paolo Gionchetti; Karen M Lammers; Fernando Rizzello; Massimo Campieri
Journal:  Gastroenterol Clin North Am       Date:  2005-09       Impact factor: 3.806

5.  An approach for developing a national estimate of waterborne disease due to drinking water and a national estimate model application.

Authors:  Michael Messner; Susan Shaw; Stig Regli; Ken Rotert; Valerie Blank; Jeff Soller
Journal:  J Water Health       Date:  2006       Impact factor: 1.744

Review 6.  Probiotics for maintenance of remission in Crohn's disease.

Authors:  V E Rolfe; P J Fortun; C J Hawkey; F Bath-Hextall
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 7.  Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea.

Authors:  H Szajewska; J Mrukowicz
Journal:  Aliment Pharmacol Ther       Date:  2005-09-01       Impact factor: 8.171

8.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study.

Authors:  K Plein; J Hotz
Journal:  Z Gastroenterol       Date:  1993-02       Impact factor: 2.000

9.  Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

Authors:  Hai-Hong Cui; Cun-Long Chen; Ji-De Wang; Yu-Jie Yang; Yong Cun; Jin-Bao Wu; Yu-Hu Liu; Han-Lei Dan; Yan-Ting Jian; Xue-Qing Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

10.  Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

Authors:  D Guyonnet; O Chassany; P Ducrotte; C Picard; M Mouret; C-H Mercier; C Matuchansky
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

View more
  5 in total

1.  How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome.

Authors:  MaryBeth Mercer; Margaret A Brinich; Gail Geller; Krista Harrison; Janelle Highland; Katherine James; Patricia Marshall; Jennifer B McCormick; Jon Tilburt; Jean-Paul Achkar; Ruth M Farrell; Richard R Sharp
Journal:  J Clin Gastroenterol       Date:  2012-02       Impact factor: 3.062

2.  Maternal perspectives on the use of probiotics in infants: a cross-sectional survey.

Authors:  Sarah L Bridgman; Meghan B Azad; Catherine J Field; Nicole Letourneau; David W Johnston; Bonnie J Kaplan; Anita L Kozyrskyj
Journal:  BMC Complement Altern Med       Date:  2014-09-29       Impact factor: 3.659

3.  Help, hope and hype: ethical considerations of human microbiome research and applications.

Authors:  Yonghui Ma; Hua Chen; Canhui Lan; Jianlin Ren
Journal:  Protein Cell       Date:  2018-05       Impact factor: 14.870

4.  "Snake-oil," "quack medicine," and "industrially cultured organisms:" biovalue and the commercialization of human microbiome research.

Authors:  Melody J Slashinski; Sheryl A McCurdy; Laura S Achenbaum; Simon N Whitney; Amy L McGuire
Journal:  BMC Med Ethics       Date:  2012-10-30       Impact factor: 2.652

Review 5.  Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide.

Authors:  A P S Hungin; C Mulligan; B Pot; P Whorwell; L Agréus; P Fracasso; C Lionis; J Mendive; J-M Philippart de Foy; G Rubin; C Winchester; N de Wit
Journal:  Aliment Pharmacol Ther       Date:  2013-08-27       Impact factor: 8.171

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.